Labcorp (LH) announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer’s disease-related data faster. Developed with Amazon Web Services (AMZN) and Datavant, the platform provides access to large, diverse datasets and advanced analytics-using deidentified, privacy-protected healthcare data-designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining. The platform will complete its initial validation phase in spring 2026 and is expected to expand through 2026, incorporating additional data sources and analytical capabilities to further accelerate research insights including inflammatory diseases, cardiometabolic conditions, women’s health and oncology.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade AMZNPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Declares Quarterly Cash Dividend, Signals Ongoing Confidence
- Labcorp price target raised to $300 from $280 at Evercore ISI
- Labcorp Sets Date for First-Quarter 2026 Results
- Labcorp Holdings Secures New $750 Million Term Loan
- Labcorp, Illumina expand collaboration to broaden access to oncology testing